DGIdb - ETANERCEPT Drug Record

ETANERCEPT chembl:CHEMBL1201572 ApprovedImmunotherapy

Alternate Names:

GP-2015
RHU-TNFR:FC
GP2015C
LBEC0101
ENBREL
ETANERCEPT
TNFR-IMMUNOADHESIN
L04AB01
GP2015
HD203
RHU TNFR:FC
BENEPALI
FC
CD120B
TUMOR NECROSIS FACTOR RECEPTOR TYPE II
TUMOR NECROSIS FACTOR RECEPTOR 2
TNF-R2
P80 TNF-ALPHA RECEPTOR
RHU TNFR
TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 1B PRECURSOR
P75
chembl:CHEMBL1201572
chemidplus:185243-69-0
drugbank:00005
rxcui:214555

Drug Info:

Drug Class	immunomodulatory agents
Year of Approval	1998
Drug Class	antirheumatic agents
FDA Approval	approved
Drug Class	fusion protein
Drug Indications	antiinflammatory agent,DMARD

(3 More Sources)

Publications:

Iwaszko M et al., 2015, Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy., Clin Exp Immunol
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Xing-Rong W et al., 2018, Role of TNFRSF1A and TNFRSF1B polymorphisms in susceptibility, severity, and therapeutic efficacy of etanercept in human leukocyte antigen-B27-positive Chinese Han patients with ankylosing spondylitis., Medicine (Baltimore)
Park et al., 1999, Structural basis for self-association and receptor recognition of human TRAF2., Nature
Calabrese, 1999, Rheumatoid arthritis and primary care: the case for early diagnosis and treatment., J Am Osteopath Assoc
Sandborn et al., 1999, Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety., Inflamm. Bowel Dis.
Moreland, 1999, Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis., Cleve Clin J Med
Grell et al., 1999, Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF., EMBO J.
Song GG et al., 2015, Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis., Pharmacogenomics
Tong Q et al., 2013, Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis., Pharmacogenomics
Tong Q et al., 2012, TNF-α -857 and -1031 polymorphisms predict good therapeutic response to TNF-α blockers in Chinese Han patients with ankylosing spondylitis., Pharmacogenomics
Lacruz-Guzmán D et al., 2013, Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis., Eur J Clin Pharmacol
Zeng Z et al., 2013, Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis., Mod Rheumatol
Daïen CI et al., 2012, TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis., Joint Bone Spine
O'Rielly DD et al., 2009, TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis., Pharmacogenomics J
Maxwell JR et al., 2008, Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis., Hum Mol Genet
Marotte H et al., 2008, Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor., Arthritis Rheum
Guis S et al., 2007, Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis., Arthritis Rheum
Cuchacovich M et al., 2006, Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis., Scand J Rheumatol
Lee YH et al., 2006, Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis., Rheumatol Int
Seitz M et al., 2007, The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients., Rheumatology (Oxford)
Mugnier B et al., 2003, Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis., Arthritis Rheum
Louis E et al., 2002, A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism., Scand J Gastroenterol
Pappas DA et al., 2013, Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis., Inflammation
Cui J et al., 2010, Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy., Arthritis Rheum
Criswell et al., 2004, The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept., Arthritis Rheum.
Hughes et al., 2004, Genetic risk factors for infection in patients with early rheumatoid arthritis., Genes Immun.
Mendrinou E et al., 2017, FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors., Pharmacogenomics J
Julià M et al., 2013, The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study., JAMA Dermatol
Hofmann HP et al., 2016, Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®))., Expert Opin Biol Ther
Arora T et al., 2009, Differences in binding and effector functions between classes of TNF antagonists., Cytokine
Agnholt et al., 2003, The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures., Cytokine
Julià A et al., 2014, PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis., Pharmacogenomics
Julià A et al., 2015, Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis., Pharmacogenomics J
Acosta-Colman I et al., 2013, GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis., Pharmacogenomics
Ovejero-Benito MC et al., 2017, Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis., Pharmacogenomics
Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine
Morales-Lara MJ et al., 2012, Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis., Joint Bone Spine
Xu et al., 2008, Ghrelin prevents doxorubicin-induced cardiotoxicity through TNF-alpha/NF-kappaB pathways and mitochondrial protective mechanisms., Toxicology
Dávila-Fajardo CL et al., 2014, Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome., Pharmacogenet Genomics
van den Reek JMPA et al., 2017, Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis., Br J Dermatol

ETANERCEPT CD84

Interaction Score: 6.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27564082

Sources:
PharmGKB
ETANERCEPT SLCO1C1

Interaction Score: 6.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25493569 25403996 23651021

Sources:
PharmGKB
ETANERCEPT FCGR2A

Interaction Score: 3.25

Interaction Types & Directionality:

ligand

Interaction Info:

PMIDs:
27044681 24048425 15457442 15526004 27463856 19128982

Sources:
PharmGKB
ETANERCEPT TRAF1

Interaction Score: 2.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23007924

Sources:
PharmGKB
ETANERCEPT TNFRSF1A

Interaction Score: 1.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22480748

Sources:
PharmGKB
ETANERCEPT KLRD1

Interaction Score: 1.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26453102

Sources:
PharmGKB
ETANERCEPT TNFRSF1B

Interaction Score: 1.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11752352 30075559

Sources:
PharmGKB
ETANERCEPT ATP5F1E

Interaction Score: 1.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26307125

Sources:
PharmGKB
ETANERCEPT IL12B

Interaction Score: 1.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28470127

Sources:
PharmGKB
ETANERCEPT TNF

Interaction Score: 1.24

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction TNF-alpha inhibitor

Trial Name Enbrel

PMIDs:
10206649 10405518 10338381 10375846 11752352 10357816 26244882 24192118 23057546 22960943 22760475 22129793 19365401 18713756 18438841 18050183 17343250 16909270 16720636 12847678 12190096

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
ETANERCEPT STAT4

Interaction Score: 1.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ETANERCEPT FCGR3A

Interaction Score: 0.95

Interaction Types & Directionality:

ligand

Interaction Info:

PMIDs:
15457442 15526004 27044681 24048425 27463856 19128982

Sources:
PharmGKB
ETANERCEPT HLA-E

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ETANERCEPT PTPRC

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23007924 20309874

Sources:
PharmGKB
ETANERCEPT PSORS1C1

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ETANERCEPT GHRL

Interaction Score: 0.54

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18400355

Sources:
NCI
ETANERCEPT IL6

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24253594

Sources:
PharmGKB
ETANERCEPT CSF2

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12906870

Sources:
NCI
ETANERCEPT HLA-DRB1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

TEND: ETANERCEPT
- Version: 01-August-2011
Alternate Names:

ETANERCEPT Primary Drug Name

Drug Info:

Drug Class antirheumatic agents

Year of Approval 1998

Drug Class immunomodulatory agents

Publications:
TdgClinicalTrial: ETANERCEPT
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiinflammatory agent,DMARD

Drug Class fusion protein

FDA Approval approved

Publications:

NCI: ETANERCEPT

Version: 14-September-2017

Alternate Names:

C2381 NCI drug code

Drug Info:

Publications:

Agnholt et al., 2003, The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures., Cytokine

Xu et al., 2008, Ghrelin prevents doxorubicin-induced cardiotoxicity through TNF-alpha/NF-kappaB pathways and mitochondrial protective mechanisms., Toxicology

PharmGKB: etanercept

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Ovejero-Benito MC et al., 2017, Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis., Pharmacogenomics

Pappas DA et al., 2013, Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis., Inflammation

Dávila-Fajardo CL et al., 2014, Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome., Pharmacogenet Genomics

TTD: Etanercept
- Version: 2020.06.01
Alternate Names:

D0I5QX TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201572
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201572
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	TNF-alpha inhibitor
Trial Name	Enbrel

antibody (inhibitory)
inhibitor (inhibitory)

ETANERCEPT Drug Record

ETANERCEPT chembl:CHEMBL1201572 ApprovedImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27564082

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25493569 25403996 23651021

Sources: PharmGKB

Interaction Types & Directionality: ligand

Interaction Info:

PMIDs: 27044681 24048425 15457442 15526004 27463856 19128982

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23007924

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22480748

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26453102

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11752352 30075559

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26307125

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28470127

Sources: PharmGKB

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction TNF-alpha inhibitor Trial Name Enbrel

PMIDs: 10206649 10405518 10338381 10375846 11752352 10357816 26244882 24192118 23057546 22960943 22760475 22129793 19365401 18713756 18438841 18050183 17343250 16909270 16720636 12847678 12190096

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: ligand

Interaction Info:

PMIDs: 15457442 15526004 27044681 24048425 27463856 19128982

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23007924 20309874

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18400355

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24253594

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12906870

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Interaction Types & Directionality:

n/a

PMIDs:
27564082

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25493569 25403996 23651021

Sources:
PharmGKB

Interaction Types & Directionality:

ligand

PMIDs:
27044681 24048425 15457442 15526004 27463856 19128982

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23007924

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22480748

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26453102

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11752352 30075559

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26307125

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28470127

Sources:
PharmGKB

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction TNF-alpha inhibitor

Trial Name Enbrel

PMIDs:
10206649 10405518 10338381 10375846 11752352 10357816 26244882 24192118 23057546 22960943 22760475 22129793 19365401 18713756 18438841 18050183 17343250 16909270 16720636 12847678 12190096

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

ligand

PMIDs:
15457442 15526004 27044681 24048425 27463856 19128982

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23007924 20309874

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18400355

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
24253594

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12906870

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Alternate Names:

ETANERCEPT Primary Drug Name

Drug Info:

Drug Class antirheumatic agents

Year of Approval 1998

Drug Class immunomodulatory agents

Drug Info:

Drug Indications antiinflammatory agent,DMARD

Drug Class fusion protein

FDA Approval approved

Alternate Names:

C2381 NCI drug code

Alternate Names:

D0I5QX TTD Drug ID